| http://dbpedia.org/ontology/abstract
|
Ivosidenib, sold under the brand name Tibs … Ivosidenib, sold under the brand name Tibsovo, is an anti-cancer medication for the treatment of acute myeloid leukemia (AML) and cholangiocarcinoma. It is a small molecule inhibitor of isocitrate dehydrogenase-1 (IDH1), which is mutated in several forms of cancer. Ivosidenib is an isocitrate dehydrogenase-1 inhibitor that works by decreasing abnormal production of the oncometabolite 2-hydroxyglutarate (2-HG), leading to differentiation of malignant cells. Ivosidenib was approved for medical use in the United States in July 2018. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.ders it to be a first-in-class medication.
, L'ivosidénib est un anticancéreux inhibiteur de l'IDH1. Il a été approuvé pour la première fois en 2018 dans le traitement des leucémies aiguës myéloïdes (LAM).
, Ivosidenib ist ein Arzneistoff, der das En … Ivosidenib ist ein Arzneistoff, der das Enzym Isocitrat-Dehydrogenase-1 (IDH1) hemmt. Mutationen in diesem Enzym spielen eine Rolle bei verschiedenen Krebserkrankungen. Als erstes (first in class) und bisher einziges Medikament mit diesem Wirkmechanismus ist es unter dem Namen Tibsovo in den USA, nicht aber in der EU, in besonderen Fällen für die Behandlung der akuten myeloischen Leukämie (AML) zugelassen. Zudem wird es für die Behandlung anderer Tumoren mit IDH1-Mutationen geprüft (Stand 2021). mit IDH1-Mutationen geprüft (Stand 2021).
|
| http://dbpedia.org/ontology/alternativeName
|
Tibsovo
|
| http://dbpedia.org/ontology/casNumber
|
1448347-49-6
|
| http://dbpedia.org/ontology/chEBI
|
145430
|
| http://dbpedia.org/ontology/chEMBL
|
3989958
|
| http://dbpedia.org/ontology/drugbank
|
DB14568
|
| http://dbpedia.org/ontology/fdaUniiCode
|
Q2PCN8MAM6
|
| http://dbpedia.org/ontology/kegg
|
D11090
|
| http://dbpedia.org/ontology/medlinePlus
|
a618042
|
| http://dbpedia.org/ontology/pubchem
|
71657455
|
| http://dbpedia.org/ontology/thumbnail
|
http://commons.wikimedia.org/wiki/Special:FilePath/Ivosidenib.svg?width=300 +
|
| http://dbpedia.org/ontology/wikiPageExternalLink
|
https://druginfo.nlm.nih.gov/drugportal/name/ivosidenib +
, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211192Orig1s000TOC.cfm +
|
| http://dbpedia.org/ontology/wikiPageID
|
55683517
|
| http://dbpedia.org/ontology/wikiPageLength
|
14049
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1090379123
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Food_and_Drug_Administration +
, http://dbpedia.org/resource/Cancer +
, http://dbpedia.org/resource/IC50 +
, http://dbpedia.org/resource/Category:Antineoplastic_drugs +
, http://dbpedia.org/resource/Anti-cancer_medication +
, http://dbpedia.org/resource/Oral_administration +
, http://dbpedia.org/resource/Category:Acute_myeloid_leukemia +
, http://dbpedia.org/resource/IDH1 +
, http://dbpedia.org/resource/Cholangiocarcinoma +
, http://dbpedia.org/resource/Non-competitive_inhibition +
, http://dbpedia.org/resource/Nicotinamide_adenine_dinucleotide_phosphate +
, http://dbpedia.org/resource/Acute_myeloid_leukemia +
, http://dbpedia.org/resource/Protein_dimer +
, http://dbpedia.org/resource/Orphan_drug +
, http://dbpedia.org/resource/Uncompetitive_inhibitor +
, http://dbpedia.org/resource/Targeted_therapy +
, http://dbpedia.org/resource/In_vitro +
, http://dbpedia.org/resource/Alpha-Ketoglutaric_acid +
, http://dbpedia.org/resource/Category:Orphan_drugs +
, http://dbpedia.org/resource/NADPH +
|
| http://dbpedia.org/property/atcPrefix
|
L01
|
| http://dbpedia.org/property/atcSuffix
|
XX62
|
| http://dbpedia.org/property/c
|
28
|
| http://dbpedia.org/property/casNumber
|
1448347
|
| http://dbpedia.org/property/chebi
|
145430
|
| http://dbpedia.org/property/chembl
|
3989958
|
| http://dbpedia.org/property/chemspiderid
|
38772333
|
| http://dbpedia.org/property/cl
|
1
|
| http://dbpedia.org/property/class
|
Antineoplastic Agents
|
| http://dbpedia.org/property/dailymedid
|
Ivosidenib
|
| http://dbpedia.org/property/drugbank
|
DB14568
|
| http://dbpedia.org/property/f
|
3
|
| http://dbpedia.org/property/h
|
22
|
| http://dbpedia.org/property/iupacName
|
-N-{-1--2-[amino]-2-oxoethyl}-1--N--5-oxopyrrolidine2-carboxamide
|
| http://dbpedia.org/property/kegg
|
D11090
|
| http://dbpedia.org/property/legalUs
|
Rx-only
|
| http://dbpedia.org/property/licenseUs
|
Tibsovo
|
| http://dbpedia.org/property/medlineplus
|
a618042
|
| http://dbpedia.org/property/n
|
6
|
| http://dbpedia.org/property/o
|
3
|
| http://dbpedia.org/property/pronounce
|
eye"voe sid' e nib
|
| http://dbpedia.org/property/pubchem
|
71657455
|
| http://dbpedia.org/property/routesOfAdministration
|
http://dbpedia.org/resource/Oral_administration +
|
| http://dbpedia.org/property/smiles
|
C1CCNC5=NC=CCC#N
|
| http://dbpedia.org/property/stdinchiComment
|
1
|
| http://dbpedia.org/property/stdinchikey
|
WIJZXSAJMHAVGX-DHLKQENFSA-N
|
| http://dbpedia.org/property/synonyms
|
AG-120
|
| http://dbpedia.org/property/tradename
|
Tibsovo
|
| http://dbpedia.org/property/unii
|
Q2PCN8MAM6
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Cite_web +
, http://dbpedia.org/resource/Template:Short_description +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Targeted_cancer_therapeutic_agents +
, http://dbpedia.org/resource/Template:Infobox_drug +
, http://dbpedia.org/resource/Template:ClinicalTrialsGov +
, http://dbpedia.org/resource/Template:Portal_bar +
, http://dbpedia.org/resource/Template:Drugs.com +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Acute_myeloid_leukemia +
, http://dbpedia.org/resource/Category:Orphan_drugs +
, http://dbpedia.org/resource/Category:Antineoplastic_drugs +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Ivosidenib?oldid=1090379123&ns=0 +
|
| http://xmlns.com/foaf/0.1/depiction
|
http://commons.wikimedia.org/wiki/Special:FilePath/Ivosidenib.svg +
|
| http://xmlns.com/foaf/0.1/homepage
|
http://U.S. +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Ivosidenib +
|
| owl:sameAs |
http://fr.dbpedia.org/resource/Ivosid%C3%A9nib +
, http://de.dbpedia.org/resource/Ivosidenib +
, https://global.dbpedia.org/id/2bZ1A +
, http://www.wikidata.org/entity/Q27895417 +
, http://dbpedia.org/resource/Ivosidenib +
|
| rdf:type |
http://dbpedia.org/ontology/Drug +
, http://dbpedia.org/ontology/ChemicalSubstance +
, http://www.wikidata.org/entity/Q8386 +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#ChemicalObject +
|
| rdfs:comment |
L'ivosidénib est un anticancéreux inhibiteur de l'IDH1. Il a été approuvé pour la première fois en 2018 dans le traitement des leucémies aiguës myéloïdes (LAM).
, Ivosidenib, sold under the brand name Tibs … Ivosidenib, sold under the brand name Tibsovo, is an anti-cancer medication for the treatment of acute myeloid leukemia (AML) and cholangiocarcinoma. It is a small molecule inhibitor of isocitrate dehydrogenase-1 (IDH1), which is mutated in several forms of cancer. Ivosidenib is an isocitrate dehydrogenase-1 inhibitor that works by decreasing abnormal production of the oncometabolite 2-hydroxyglutarate (2-HG), leading to differentiation of malignant cells.ing to differentiation of malignant cells.
, Ivosidenib ist ein Arzneistoff, der das En … Ivosidenib ist ein Arzneistoff, der das Enzym Isocitrat-Dehydrogenase-1 (IDH1) hemmt. Mutationen in diesem Enzym spielen eine Rolle bei verschiedenen Krebserkrankungen. Als erstes (first in class) und bisher einziges Medikament mit diesem Wirkmechanismus ist es unter dem Namen Tibsovo in den USA, nicht aber in der EU, in besonderen Fällen für die Behandlung der akuten myeloischen Leukämie (AML) zugelassen. Zudem wird es für die Behandlung anderer Tumoren mit IDH1-Mutationen geprüft (Stand 2021). mit IDH1-Mutationen geprüft (Stand 2021).
|
| rdfs:label |
Ivosidenib
, Ivosidénib
|
